Nanosphere Ends Yearly Revenue up on Verigene Sales

The molecular diagnostics developer's full-year sales swelled 16 percent, as it plans to file for regulatory clearance for a variety of tests.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.